Aliza Brown
Concepts (242)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stroke | 12 | 2020 | 492 | 2.140 |
Why?
| Thrombolytic Therapy | 8 | 2020 | 111 | 1.210 |
Why?
| Tissue Plasminogen Activator | 9 | 2020 | 110 | 1.170 |
Why?
| Endarterectomy, Carotid | 9 | 2011 | 62 | 0.910 |
Why?
| Health Services Misuse | 1 | 2020 | 13 | 0.720 |
Why?
| Fibrinolytic Agents | 7 | 2020 | 125 | 0.720 |
Why?
| Tunica Intima | 8 | 2011 | 55 | 0.710 |
Why?
| Homocysteine | 7 | 2011 | 128 | 0.670 |
Why?
| Disease Models, Animal | 12 | 2015 | 1451 | 0.600 |
Why?
| Microbubbles | 3 | 2011 | 25 | 0.580 |
Why?
| Pneumonia, Viral | 1 | 2020 | 168 | 0.580 |
Why?
| Emergency Service, Hospital | 2 | 2020 | 488 | 0.570 |
Why?
| Coronavirus Infections | 1 | 2020 | 178 | 0.570 |
Why?
| Emergency Medical Technicians | 1 | 2016 | 10 | 0.550 |
Why?
| Carotid Arteries | 6 | 2010 | 85 | 0.550 |
Why?
| Fluorocarbons | 4 | 2019 | 45 | 0.520 |
Why?
| Emergency Medical Services | 1 | 2016 | 111 | 0.510 |
Why?
| Ultrasonic Therapy | 3 | 2011 | 32 | 0.500 |
Why?
| Acetaminophen | 3 | 2011 | 282 | 0.480 |
Why?
| Acetylcysteine | 2 | 2011 | 100 | 0.480 |
Why?
| Quality Improvement | 1 | 2016 | 212 | 0.470 |
Why?
| Cerebral Hemorrhage | 3 | 2015 | 104 | 0.410 |
Why?
| Rural Population | 1 | 2016 | 535 | 0.400 |
Why?
| Brain Ischemia | 4 | 2019 | 161 | 0.400 |
Why?
| Liver Failure, Acute | 1 | 2011 | 53 | 0.390 |
Why?
| Intracranial Embolism | 2 | 2012 | 27 | 0.380 |
Why?
| Rabbits | 10 | 2016 | 370 | 0.370 |
Why?
| Carotid Stenosis | 4 | 2011 | 63 | 0.320 |
Why?
| Animals | 26 | 2016 | 13150 | 0.300 |
Why?
| Time Factors | 11 | 2020 | 2912 | 0.280 |
Why?
| Neuroprotective Agents | 2 | 2019 | 105 | 0.280 |
Why?
| Insulin Resistance | 2 | 2010 | 264 | 0.270 |
Why?
| Magnetic Resonance Imaging | 2 | 2014 | 1533 | 0.260 |
Why?
| Platelet Aggregation Inhibitors | 4 | 2006 | 174 | 0.220 |
Why?
| Brain | 1 | 2010 | 1309 | 0.200 |
Why?
| Rats | 12 | 2011 | 3300 | 0.190 |
Why?
| United States | 4 | 2020 | 4838 | 0.190 |
Why?
| Rats, Sprague-Dawley | 9 | 2011 | 1595 | 0.190 |
Why?
| Hyperplasia | 8 | 2011 | 99 | 0.180 |
Why?
| Male | 21 | 2019 | 25093 | 0.180 |
Why?
| Conflict of Interest | 1 | 2020 | 25 | 0.170 |
Why?
| Thrombectomy | 1 | 2020 | 66 | 0.170 |
Why?
| Disease Outbreaks | 1 | 2020 | 125 | 0.170 |
Why?
| Fabry Disease | 1 | 2019 | 9 | 0.170 |
Why?
| Enzyme Replacement Therapy | 1 | 2019 | 17 | 0.170 |
Why?
| Angiography, Digital Subtraction | 2 | 2011 | 27 | 0.170 |
Why?
| Carotid Artery, Common | 2 | 2011 | 44 | 0.160 |
Why?
| Ischemic Attack, Transient | 1 | 2019 | 56 | 0.160 |
Why?
| Cardiology | 1 | 2020 | 89 | 0.160 |
Why?
| Cerebral Angiography | 3 | 2012 | 96 | 0.150 |
Why?
| Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 2004 | 57 | 0.130 |
Why?
| Infarction, Anterior Cerebral Artery | 1 | 2015 | 2 | 0.130 |
Why?
| Pandemics | 1 | 2020 | 554 | 0.130 |
Why?
| Infarction, Middle Cerebral Artery | 1 | 2015 | 40 | 0.130 |
Why?
| Ticlopidine | 2 | 2006 | 55 | 0.120 |
Why?
| Antidotes | 2 | 2011 | 29 | 0.120 |
Why?
| Humans | 12 | 2020 | 49827 | 0.120 |
Why?
| Salivary Proteins and Peptides | 2 | 2004 | 8 | 0.120 |
Why?
| Receptors, N-Methyl-D-Aspartate | 2 | 2005 | 126 | 0.120 |
Why?
| L-Lactate Dehydrogenase | 1 | 2014 | 65 | 0.120 |
Why?
| Posterior Leukoencephalopathy Syndrome | 1 | 2014 | 44 | 0.110 |
Why?
| Fractures, Compression | 1 | 2013 | 17 | 0.110 |
Why?
| Fractures, Spontaneous | 1 | 2013 | 16 | 0.110 |
Why?
| Models, Animal | 4 | 2011 | 233 | 0.110 |
Why?
| Telemedicine | 1 | 2019 | 443 | 0.110 |
Why?
| Treatment Outcome | 5 | 2019 | 5138 | 0.110 |
Why?
| Spine | 1 | 2013 | 94 | 0.110 |
Why?
| Expectorants | 1 | 2011 | 14 | 0.100 |
Why?
| Echinomycin | 1 | 2011 | 6 | 0.100 |
Why?
| Carotid Artery Injuries | 1 | 2011 | 13 | 0.100 |
Why?
| Analysis of Variance | 2 | 2011 | 565 | 0.100 |
Why?
| Statistics as Topic | 1 | 2011 | 89 | 0.100 |
Why?
| Circle of Willis | 1 | 2011 | 2 | 0.100 |
Why?
| Sensitivity and Specificity | 2 | 2011 | 854 | 0.100 |
Why?
| Cerebral Infarction | 1 | 2011 | 39 | 0.100 |
Why?
| Ultrasonography, Doppler, Transcranial | 1 | 2011 | 24 | 0.100 |
Why?
| Intracranial Hemorrhages | 1 | 2011 | 39 | 0.100 |
Why?
| Sinus Thrombosis, Intracranial | 1 | 2010 | 17 | 0.090 |
Why?
| Acarbose | 1 | 2010 | 2 | 0.090 |
Why?
| Receptors, Adrenergic, beta-2 | 1 | 2000 | 16 | 0.090 |
Why?
| Indocyanine Green | 1 | 2010 | 34 | 0.090 |
Why?
| Analgesics, Non-Narcotic | 1 | 2011 | 116 | 0.090 |
Why?
| Hepatocytes | 1 | 2011 | 181 | 0.090 |
Why?
| Estradiol | 1 | 2011 | 225 | 0.090 |
Why?
| Trachea | 1 | 2000 | 51 | 0.090 |
Why?
| Subarachnoid Hemorrhage | 1 | 2010 | 65 | 0.090 |
Why?
| Ultrasonography, Interventional | 1 | 2010 | 135 | 0.090 |
Why?
| Female | 11 | 2019 | 26329 | 0.080 |
Why?
| Arkansas | 3 | 2019 | 1967 | 0.080 |
Why?
| Radiography | 1 | 2010 | 489 | 0.080 |
Why?
| Hypoglycemic Agents | 1 | 2010 | 166 | 0.080 |
Why?
| Glucocorticoids | 1 | 2000 | 219 | 0.080 |
Why?
| Dietary Sucrose | 2 | 2010 | 14 | 0.080 |
Why?
| Dexamethasone | 1 | 2000 | 429 | 0.080 |
Why?
| Cystathionine beta-Synthase | 2 | 2004 | 17 | 0.080 |
Why?
| Reproducibility of Results | 1 | 2011 | 1188 | 0.080 |
Why?
| Ketorolac Tromethamine | 1 | 2007 | 2 | 0.080 |
Why?
| Myocytes, Smooth Muscle | 2 | 2005 | 87 | 0.080 |
Why?
| Cyclooxygenase Inhibitors | 1 | 2007 | 39 | 0.070 |
Why?
| Cerebral Veins | 1 | 2007 | 15 | 0.070 |
Why?
| Recovery of Function | 2 | 2019 | 189 | 0.070 |
Why?
| Mice | 3 | 2011 | 5720 | 0.070 |
Why?
| Cerebral Arteries | 1 | 2007 | 40 | 0.070 |
Why?
| Drug Administration Schedule | 2 | 2019 | 376 | 0.070 |
Why?
| Middle Aged | 6 | 2019 | 11997 | 0.070 |
Why?
| Random Allocation | 3 | 2015 | 280 | 0.070 |
Why?
| Pravastatin | 1 | 2006 | 18 | 0.070 |
Why?
| Insulin | 2 | 2010 | 457 | 0.070 |
Why?
| Antineoplastic Agents | 1 | 2014 | 1172 | 0.070 |
Why?
| Antioxidants | 1 | 2007 | 248 | 0.060 |
Why?
| Constriction | 1 | 2004 | 9 | 0.060 |
Why?
| Liver | 1 | 2010 | 1109 | 0.060 |
Why?
| Platelet Aggregation | 1 | 2005 | 71 | 0.060 |
Why?
| Smoke | 1 | 2004 | 18 | 0.060 |
Why?
| Blood Platelets | 2 | 2006 | 245 | 0.060 |
Why?
| Muscle, Smooth, Vascular | 1 | 2005 | 131 | 0.060 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 138 | 0.060 |
Why?
| Cell Division | 1 | 2005 | 292 | 0.060 |
Why?
| Aged | 5 | 2019 | 9272 | 0.060 |
Why?
| Databases, Factual | 2 | 2020 | 664 | 0.060 |
Why?
| Neoplasms | 1 | 2014 | 1233 | 0.060 |
Why?
| Emulsions | 2 | 2015 | 24 | 0.060 |
Why?
| Cystathionine gamma-Lyase | 1 | 2003 | 4 | 0.060 |
Why?
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2003 | 16 | 0.060 |
Why?
| Endothelium, Vascular | 1 | 2005 | 254 | 0.060 |
Why?
| Postoperative Period | 1 | 2004 | 172 | 0.060 |
Why?
| Saphenous Vein | 1 | 2004 | 65 | 0.060 |
Why?
| Arterial Occlusive Diseases | 1 | 2004 | 81 | 0.050 |
Why?
| Lower Extremity | 1 | 2004 | 88 | 0.050 |
Why?
| Oxidative Stress | 1 | 2007 | 768 | 0.050 |
Why?
| Dietary Carbohydrates | 1 | 2003 | 88 | 0.050 |
Why?
| Diet | 2 | 2005 | 564 | 0.050 |
Why?
| Dietary Fats | 1 | 2003 | 133 | 0.050 |
Why?
| Preoperative Care | 1 | 2004 | 167 | 0.050 |
Why?
| Folic Acid | 1 | 2003 | 135 | 0.050 |
Why?
| Collagen | 1 | 2003 | 206 | 0.050 |
Why?
| Renal Dialysis | 1 | 2003 | 169 | 0.050 |
Why?
| Retrospective Studies | 3 | 2019 | 6117 | 0.050 |
Why?
| Dose-Response Relationship, Drug | 3 | 2011 | 1374 | 0.050 |
Why?
| Health Care Sector | 1 | 2020 | 15 | 0.040 |
Why?
| Drug Industry | 1 | 2020 | 38 | 0.040 |
Why?
| Tomography, X-Ray Computed | 2 | 2018 | 1159 | 0.040 |
Why?
| Maximum Tolerated Dose | 1 | 2019 | 37 | 0.040 |
Why?
| alpha-Galactosidase | 1 | 2019 | 9 | 0.040 |
Why?
| Administration, Intravenous | 1 | 2019 | 68 | 0.040 |
Why?
| Disability Evaluation | 1 | 2019 | 87 | 0.040 |
Why?
| Multiple Myeloma | 1 | 2013 | 2910 | 0.040 |
Why?
| Cell Count | 2 | 2005 | 146 | 0.040 |
Why?
| Double-Blind Method | 1 | 2019 | 674 | 0.040 |
Why?
| Referral and Consultation | 1 | 2019 | 287 | 0.040 |
Why?
| Glutamates | 1 | 2016 | 21 | 0.040 |
Why?
| Blotting, Western | 2 | 2005 | 602 | 0.030 |
Why?
| Angiography | 1 | 2016 | 126 | 0.030 |
Why?
| Gene Expression Regulation | 2 | 2011 | 979 | 0.030 |
Why?
| Single-Blind Method | 1 | 2015 | 116 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2015 | 144 | 0.030 |
Why?
| Infusions, Intravenous | 1 | 2015 | 207 | 0.030 |
Why?
| Reperfusion Injury | 1 | 2015 | 87 | 0.030 |
Why?
| Blood Chemical Analysis | 1 | 2014 | 27 | 0.030 |
Why?
| Adult | 3 | 2014 | 13160 | 0.030 |
Why?
| Immunohistochemistry | 2 | 2005 | 971 | 0.030 |
Why?
| Infusion Pumps, Implantable | 1 | 2011 | 13 | 0.030 |
Why?
| Angioplasty | 1 | 2011 | 20 | 0.030 |
Why?
| Proliferating Cell Nuclear Antigen | 1 | 2011 | 75 | 0.020 |
Why?
| Hyperhomocysteinemia | 1 | 2011 | 29 | 0.020 |
Why?
| Jugular Veins | 1 | 2011 | 31 | 0.020 |
Why?
| Liver Regeneration | 1 | 2011 | 49 | 0.020 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 56 | 0.020 |
Why?
| Estrogen Replacement Therapy | 1 | 2011 | 41 | 0.020 |
Why?
| Ovariectomy | 1 | 2011 | 119 | 0.020 |
Why?
| Statistics, Nonparametric | 1 | 2011 | 197 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2011 | 282 | 0.020 |
Why?
| Adrenergic beta-2 Receptor Agonists | 1 | 2000 | 2 | 0.020 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2011 | 201 | 0.020 |
Why?
| Ultrasonography, Doppler, Pulsed | 1 | 2010 | 2 | 0.020 |
Why?
| Coloring Agents | 1 | 2010 | 71 | 0.020 |
Why?
| Injections, Intravenous | 1 | 2010 | 140 | 0.020 |
Why?
| Isoproterenol | 1 | 2000 | 57 | 0.020 |
Why?
| Adrenergic beta-Agonists | 1 | 2000 | 40 | 0.020 |
Why?
| Phlebography | 1 | 2010 | 62 | 0.020 |
Why?
| Luciferases | 1 | 2000 | 50 | 0.020 |
Why?
| Mice, Inbred Strains | 1 | 2010 | 161 | 0.020 |
Why?
| Epithelium | 1 | 2000 | 65 | 0.020 |
Why?
| Alanine Transaminase | 1 | 2010 | 124 | 0.020 |
Why?
| Blood Flow Velocity | 1 | 2010 | 99 | 0.020 |
Why?
| Regional Blood Flow | 1 | 2010 | 108 | 0.020 |
Why?
| Cyclic AMP | 1 | 2000 | 90 | 0.020 |
Why?
| Propranolol | 1 | 2000 | 78 | 0.020 |
Why?
| Norepinephrine | 1 | 2000 | 107 | 0.020 |
Why?
| Epinephrine | 1 | 2000 | 96 | 0.020 |
Why?
| Transfection | 1 | 2000 | 357 | 0.020 |
Why?
| Cell Membrane | 1 | 2000 | 248 | 0.020 |
Why?
| Ultrasonography | 1 | 2011 | 436 | 0.020 |
Why?
| Transcription, Genetic | 1 | 2000 | 371 | 0.020 |
Why?
| DNA | 1 | 2011 | 545 | 0.020 |
Why?
| Malondialdehyde | 1 | 2007 | 51 | 0.020 |
Why?
| Blood Glucose | 1 | 2010 | 432 | 0.020 |
Why?
| Cell Line | 1 | 2000 | 1002 | 0.020 |
Why?
| Platelet Activation | 1 | 2007 | 46 | 0.020 |
Why?
| Triiodobenzoic Acids | 1 | 2007 | 9 | 0.020 |
Why?
| Glutathione | 1 | 2007 | 295 | 0.020 |
Why?
| Aged, 80 and over | 1 | 2013 | 3125 | 0.020 |
Why?
| Drug Combinations | 1 | 2006 | 123 | 0.020 |
Why?
| Contrast Media | 1 | 2007 | 183 | 0.020 |
Why?
| Dizocilpine Maleate | 1 | 2005 | 15 | 0.020 |
Why?
| Interleukin-1 | 1 | 2005 | 104 | 0.020 |
Why?
| Cholesterol | 1 | 2006 | 146 | 0.020 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2005 | 86 | 0.020 |
Why?
| Homocystine | 1 | 2004 | 8 | 0.020 |
Why?
| Excitatory Amino Acid Antagonists | 1 | 2005 | 50 | 0.020 |
Why?
| DNA, Complementary | 1 | 2005 | 135 | 0.020 |
Why?
| Platelet Function Tests | 1 | 2004 | 17 | 0.020 |
Why?
| Cell Culture Techniques | 1 | 2005 | 99 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2006 | 142 | 0.020 |
Why?
| Aorta, Thoracic | 1 | 2005 | 92 | 0.020 |
Why?
| Cotinine | 1 | 2004 | 22 | 0.020 |
Why?
| Probability | 1 | 2004 | 164 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2007 | 942 | 0.010 |
Why?
| Cell Movement | 1 | 2005 | 247 | 0.010 |
Why?
| Reference Values | 1 | 2004 | 310 | 0.010 |
Why?
| RNA | 1 | 2005 | 170 | 0.010 |
Why?
| Biopsy, Needle | 1 | 2004 | 183 | 0.010 |
Why?
| Ultrasonography, Doppler, Duplex | 1 | 2004 | 21 | 0.010 |
Why?
| Arginine | 1 | 2005 | 179 | 0.010 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 595 | 0.010 |
Why?
| Young Adult | 1 | 2013 | 3936 | 0.010 |
Why?
| Platelet Adhesiveness | 1 | 2003 | 13 | 0.010 |
Why?
| Signal Transduction | 1 | 2000 | 1617 | 0.010 |
Why?
| Elastin | 1 | 2003 | 22 | 0.010 |
Why?
| Polytetrafluoroethylene | 1 | 2003 | 32 | 0.010 |
Why?
| Nitric Oxide | 1 | 2005 | 253 | 0.010 |
Why?
| Anastomosis, Surgical | 1 | 2003 | 68 | 0.010 |
Why?
| Vascular Patency | 1 | 2003 | 83 | 0.010 |
Why?
| Dogs | 1 | 2003 | 182 | 0.010 |
Why?
| Graft Occlusion, Vascular | 1 | 2003 | 74 | 0.010 |
Why?
| Extracellular Matrix | 1 | 2003 | 111 | 0.010 |
Why?
| Gene Expression | 1 | 2005 | 608 | 0.010 |
Why?
| RNA, Messenger | 1 | 2005 | 1105 | 0.010 |
Why?
| Adolescent | 1 | 2013 | 6340 | 0.010 |
Why?
| Cells, Cultured | 1 | 2005 | 1571 | 0.010 |
Why?
| Cell Proliferation | 1 | 2005 | 1007 | 0.010 |
Why?
| Models, Biological | 1 | 2003 | 728 | 0.010 |
Why?
|
|
Brown's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|